AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)
Principal Investigator
Mitul Gandhi, MDLocations
Alexandria Office
Arlington Office
Fairfax Office
Gainesville Office
Loudoun Office
Learn More About This Trial
Other Relevant Trials
“An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)”
Principal Investigator
Mitul Gandhi, MD“A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)”
